Vor Bio says China approved telitacicept for IgA nephropathy and Sjögren's disease
Vor Bio announced that China's National Medicinal Products Administration granted conditional approval of telitacicept for adult IgA nephropathy and approval for adult Sjögren's disease, both in China, where partner RemeGen holds development and commercialization rights. Vor Bio holds exclusive rights outside Greater China, so the filing signals progress on the drug's global program but no direct financial figures are disclosed.
Key points
- NMPA conditionally approved telitacicept for adult IgA nephropathy in China, per Exhibit 99.1.
- NMPA approved telitacicept for adult Sjögren's disease in China, per Exhibit 99.2.
- In the Phase 3 TELIGAN trial, telitacicept 240 mg produced a 55% placebo-adjusted reduction in UPCR at Week 39.
- RemeGen runs development and commercialization in China; Vor Bio holds rights outside Greater China.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.